Methods of Preventing Platelet Alloimmunization and Alloimmune Platelet Refractoriness in Transfused Recipients

USPTO issued patent grant US12599667B2 to BLOODWORKS for methods of preventing platelet alloimmunization and alloimmune platelet refractoriness in transfused recipients. The invention involves modifying donor whole blood or platelets prior to transfusion to prevent or reduce complications associated with platelet transfusion. The patent was granted on April 14, 2026, with 15 claims. CPC classifications indicate the patent relates to medical device technology for handling and treating blood components.

For healthcare providers and blood banking facilities, this patent establishes intellectual property rights that may affect how platelet transfusion methods are practiced. The patent covers therapeutic methods for reducing alloimmune complications in patients receiving platelet transfusions, which is relevant to transfusion medicine and blood banking services. Parties developing similar methods or technologies should review potential patent claims for licensing or design-around considerations.